75 related articles for article (PubMed ID: 9152416)
1. Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies.
Schutten M; Andeweg AC; Rimmelzwaan GF; Osterhaus AD
J Gen Virol; 1997 May; 78 ( Pt 5)():999-1006. PubMed ID: 9152416
[TBL] [Abstract][Full Text] [Related]
2. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
[TBL] [Abstract][Full Text] [Related]
4. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
McKeating JA; Zhang YJ; Arnold C; Frederiksson R; Fenyö EM; Balfe P
Virology; 1996 Jun; 220(2):450-60. PubMed ID: 8661395
[TBL] [Abstract][Full Text] [Related]
5. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
[TBL] [Abstract][Full Text] [Related]
6. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
Sullivan N; Sun Y; Binley J; Lee J; Barbas CF; Parren PW; Burton DR; Sodroski J
J Virol; 1998 Aug; 72(8):6332-8. PubMed ID: 9658072
[TBL] [Abstract][Full Text] [Related]
7. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization.
Fouts TR; Trkola A; Fung MS; Moore JP
AIDS Res Hum Retroviruses; 1998 May; 14(7):591-7. PubMed ID: 9591713
[TBL] [Abstract][Full Text] [Related]
8. Epitopes of HIV-1 glycoproteins recognized by the human immune system.
Laal S; Zolla-Pazner S
Chem Immunol; 1993; 56():91-111. PubMed ID: 7680869
[No Abstract] [Full Text] [Related]
9. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
10. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
Neurath AR; Strick N; Lee ES
J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
[TBL] [Abstract][Full Text] [Related]
11. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
12. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
13. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
Schønning K; Jansson B; Olofsson S; Hansen JE
J Gen Virol; 1996 Apr; 77 ( Pt 4)():753-8. PubMed ID: 8627264
[TBL] [Abstract][Full Text] [Related]
14. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
[TBL] [Abstract][Full Text] [Related]
17. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.
Gorny MK; Zolla-Pazner S
J Virol; 2000 Jul; 74(13):6186-92. PubMed ID: 10846104
[TBL] [Abstract][Full Text] [Related]
18. Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies.
Nádas A; Zhong P; Burda S; Zekeng L; Urbanski M; Gorny MK; Zolla-Pazner S; Nyambi PN
AIDS Res Hum Retroviruses; 2004 Jan; 20(1):55-65. PubMed ID: 15000699
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies.
D'Souza MP; Milman G; Bradac JA; McPhee D; Hanson CV; Hendry RM
AIDS; 1995 Aug; 9(8):867-74. PubMed ID: 7576320
[TBL] [Abstract][Full Text] [Related]
20. Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine.
Stephens DM; Eichberg JW; Haigwood NL; Steimer KS; Davis D; Lachmann PJ
J Gen Virol; 1992 May; 73 ( Pt 5)():1099-106. PubMed ID: 1375277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
